Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zapping the brain back to life: could DBS reawaken cognition after severe head trauma?

NCT ID NCT07730099

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study tests whether deep brain stimulation (DBS) — a device that sends gentle electrical pulses to a key brain region — is safe and usable for people with chronic moderate to severe traumatic brain injury. Forty adults who are at least two years past their injury will receive the implant and be followed for three months. The goal is to see if the approach can improve thinking and daily function, starting with a careful check on safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deep brain stimulation (DBS) — an implantable device that delivers continuous, low-voltage electrical pulses to deep brain regions.
What this could lead to
If safe and effective, this approach could offer a new way to improve cognitive function and daily living for people with long-term brain injury.
What could go wrong
This is a small, early feasibility study focused on safety, not proof of benefit. The surgical implantation carries risks like infection, bleeding, or hardware complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2027

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 74 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. History of moderate to severe TBI based on estimated worst Glasgow Coma Scale (GCS) score within first 48 hours of injury (acceptable GCS range = 3-12) 2. Age ≥18 and \<75 years at the time of informed consent. 3. At least 24 months from date of TBI injury 4. Fluent in local language and able to independently provide consent 5. Rating of upper moderate disability to lower good recovery on the Glasgow Outcome Scale-Extended (GOSE) at time of enrollment (acceptable GOSE range 5-7) 6. Failure to return to pre-injury level of vocational or educational function 7. Either receiving no CNS stimulants or other medications known to affect cognitive function, or on stable doses of these medications for at least last three months prior to signing consent. Exclusion Criteria: 1. History of major developmental, neurologic, psychiatric or substance use disorder with evidence of disability prior to onset of TBI 2. Any DSM-5 personality disorder diagnosis, as determined by SCID-5-PD, will exclude the participant. 3. Major medical co-morbidities: end stage renal failure, heart failure, severe congestive heart disease, coagulopathy, severe respiratory problems, liver failure, uncontrolled hypertension or other significant medical co-morbidities. 4. Receiving anti-epileptic medications to control active seizures 5. Have had a documented seizure within 3 months prior to signing consent 6. Malignancy with \< 5 years life expectancy. 7. Untreated / uncontrolled (severe at the time of enrollment) depression or other psychiatric disorder. 8. Women of childbearing age who do not regularly use an accepted contraceptive method. Participants who become pregnant after enrollment may be excluded from the study. Those who become pregnant prior to the surgical implantation of the DBS system will be excluded from the study. 9. Inability to stop Coumadin or platelet anti-aggregation therapy before, during and after surgery. 10. Previous DBS or other brain implants 11. Previous ablative intracranial surgery 12. Implantable hardware not compatible with MRI or unwilling to undergo MRI (e.g. claustrophobia) 13. Condition requiring diathermy after DBS implantation 14. Hardware, lesions or other factors limiting placement of electrodes in optimal target location in the judgment of the implanting surgeon 15. Concurrent enrollment in any other clinical trial 16. Any condition that, in the judgment of the PI, significantly increases risk or significantly reduces the likelihood of benefit from DBS

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic traumatic brain injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.